QQ客服 官方微博 反馈留言

	Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
	Zhao, Guiyu; Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiao'e; Wang, Guixia; Zhao, Wenjuan
刊名	LANCET DIABETES & ENDOCRINOLOGY
	2018
卷号	6期号:8
ISSN号	2213-8587
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3538020
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Zhao, Guiyu,Zhu, Dalong,Gan, Shenglian,et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study[J]. LANCET DIABETES & ENDOCRINOLOGY,2018,6(8).
APA	Zhao, Guiyu.,Zhu, Dalong.,Gan, Shenglian.,Liu, Yu.,Ma, Jianhua.,...&Chen, Li.(2018).Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.LANCET DIABETES & ENDOCRINOLOGY,6(8).
MLA	Zhao, Guiyu,et al."Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study".LANCET DIABETES & ENDOCRINOLOGY 6.8(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。